RavenQuest BioMed Comments on Historic Senate Vote Passing Canada's Cannabis Act
VANCOUVER, British Columbia, June 20, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc.(CSE:RQB) (OTCQB:RVVQF) (Franfurt:1IT) (the “Company” or “RavenQuest”) comments on the historic vote in Canada's upper chamber on June 19, 2018 which passed with 52 Yeas, 29 Nays and 2 abstentions. Under Canada's constitution, Bill C-45 ("The Cannabis Act") will now be sent to the Governor General to make Royal Ascent, at which point it will become the law of the land; adult recreational use cannabis will be federally legal across Canada.
George Robinson, CEO of RavenQuest BioMed Inc., a diversified cannabis company based in Vancouver, BC, Canada, commented on this historic result with the following comments:
"We are extremely pleased and welcome the passage of this historic bill into law. We wish to thank the contributions from all sides of the ongoing conversation around cannabis legalization. This includes the crucial and often risky early efforts by activists and advocates as well as the ongoing contributions from educators, research scientists, law enforcement, public health officials, physicians, lawmakers and so many more. We encourage all stakeholders to continue this conversation as we move towards implementing the regulatory framework which will put this legislation into action. Much needs to be accomplished to ensure public safety, education and awareness come to the forefront as we implement C-45. As a company that believes emphatically in social responsibility, we continue to emphasize the Government of Canada's stated priority to include Indigenous communities in all major new economies affecting Canadians. We are confident that the appropriate steps will be taken by parliament and its committees to ensure Indigenous communities are afforded the chance to participate in this unprecedented economic opportunity."
Robinson added "Canada will now officially become the first G7 nation to legalize adult recreational marijuana use federally. After 90 years of prohibition, this is a historic milestone with potentially global implications. The world will be watching as Canada takes a leadership role in lifting prohibition. As we move toward the implementation of the Cannabis Act, I encourage all industry participants to lead responsibly, taking the care and caution that comes with stewardship of a new era."
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.
RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta, whose combined annual production will total 11,000 kg beginning in late 2018.
RavenQuest maintains a research partnership with Montreal's McGill University focussed upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.
The Company focusses on partnerships with Indigenous communities and has announced an MOU to construct a 250,000 square foot cannabis production facility on sovereign land of Fort McMurray First Nation #468. The facility, using RavenQuest's revolutionary grow methodology, Orbital Garden 2.0, will produce 50,000 kg of cannabis annually.
RavenQuest has also recently announced an LOI to acquire Western Agripharma Ltd., a late stage application with a 125,000 square foot facility under construction on British Columbia's sunshine coast, a short ferry ride from Vancouver, BC. Upon completion, the facility will produce 25,000 kg of cannabis annually.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
"George Robinson"
Chief Executive Officer
| For further information, please contact: | Mathieu McDonald, Corporate Communications |
| 604-484-1230 |
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
U.S. FDA Approves Gilead Sciences' (Nasdaq: GILD) Antiviral Veklury (remdesivir) for the Treatment of COVID-19
